NCT03689153 is a Phase 1 clinical trial of JNJ-63733657 in Healthy, sponsored by Janssen Pharmaceutical K.K..

Who is sponsoring NCT03689153?

NCT03689153 is sponsored by Janssen Pharmaceutical K.K..

What drugs are being tested in NCT03689153?

Interventions in NCT03689153: JNJ-63733657, Placebo.

Is NCT03689153 still recruiting?

NCT03689153 is currently completed. Last updated 28 April 2025.

Last reviewed 2025-04-28 · How we verify

NCT03689153

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-63733657 in Healthy Japanese Participants

Completed Phase 1 Last updated 28 April 2025

What this trial tests

Phase 1 trial testing JNJ-63733657 in Healthy in 24 participants. Completed in 11 July 2019.

Timeline

28 September 2018

Primary endpoint
11 July 2019

11 July 2019

Quick facts

Lead sponsor	Janssen Pharmaceutical K.K.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	28 September 2018
Primary completion	11 July 2019
Estimated completion	11 July 2019
Sites	1 location across Japan

Drugs / interventions tested

JNJ-63733657 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Janssen Pharmaceutical K.K. — full company profile →

Who can join

Adults 55 to 75, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and tolerability of JNJ-63733657 following single ascending intravenous (IV) dose administration in healthy Japanese participants.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation.
Chen Y, Yu Y. · · 2023 · cited 275× · PMID 37452321 · DOI 10.1186/s12974-023-02853-3
Tau-targeting therapies for Alzheimer disease: current status and future directions.
Congdon EE, Ji C, Tetlow AM, Jiang Y, et al · · 2023 · cited 246× · PMID 37875627 · DOI 10.1038/s41582-023-00883-2
GSK-3 and Tau: A Key Duet in Alzheimer's Disease.
Sayas CL, Ávila J. · · 2021 · cited 187× · PMID 33804962 · DOI 10.3390/cells10040721
"Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.
Xia Y, Prokop S, Giasson BI. · · 2021 · cited 160× · PMID 34090488 · DOI 10.1186/s13024-021-00460-5
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.
Plotkin SS, Cashman NR. · · 2020 · cited 106× · PMID 32682954 · DOI 10.1016/j.nbd.2020.105010
New Insights Into Drug Discovery Targeting Tau Protein.
Soeda Y, Takashima A. · · 2020 · cited 91× · PMID 33343298 · DOI 10.3389/fnmol.2020.590896
Current Status of Clinical Trials on Tau Immunotherapies.
Ji C, Sigurdsson EM. · · 2021 · cited 79× · PMID 34101156 · DOI 10.1007/s40265-021-01546-6
The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges.
Zheng H, Sun H, Cai Q, Tai HC. · · 2024 · cited 37× · PMID 38732197 · DOI 10.3390/ijms25094969

Verify or expand the search:

Other trials of JNJ-63733657

Trials testing the same drug.

NCT05407818 — A Study of JNJ-63733657 in Healthy Chinese Participants · Phase 1 · completed
NCT04619420 — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease · Phase 2 · terminated
NCT03375697 — A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subject · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Janssen Pharmaceutical K.K. trials

Trials by the same sponsor.

NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
NCT05926583 — A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa · Phase 3 · active not recruiting
NCT05567185 — A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer · Phase 1 · active not recruiting
NCT05167825 — A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension · Phase 3 · completed
NCT05242432 — A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03689153 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Pharmaceutical K.K.
Last refreshed: 28 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03689153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing